WTO, the Doha Round and Dispute Settlement — Intellectual Property Rights II Notes

WTO, the Doha Round and Dispute Settlement

TRIPS would be toothless without a court to enforce it — and that is exactly what the older WIPO treaties lacked. The World Trade Organization, born on 1 January 1995, supplied the teeth: a binding dispute-settlement system that can authorise trade retaliation against a rule-breaker. Then, in 2001, poorer nations pushed back at Doha, winning a landmark declaration that TRIPS “does not and should not prevent members from taking measures to protect public health” — the moment access to cheap medicines was written into world IP law.

The World Trade Organization (WTO) was established by the Marrakesh Agreement (1994) and began work on 1 January 1995, replacing the old GATT (General Agreement on Tariffs and Trade, 1947). It administers the world trade agreements, including TRIPS, and gives IP rules something the WIPO conventions never had — enforcement.

A. Dispute settlement

If one member believes another is breaking TRIPS, it may bring a complaint under the WTO’s Dispute Settlement Understanding (DSU), run by the Dispute Settlement Body (DSB). The stages are:

Consultations — the parties first try to settle by negotiation.
Panel — if that fails, a panel of experts hears the dispute and issues a report.
Appellate Body — either party may appeal on points of law.
Adoption and implementation — the losing member must bring its law into line.
Retaliation — if it does not, the winner may be authorised to suspend trade concessions (impose sanctions). This binding sanction is the teeth TRIPS added to international IP.

B. The Doha Round and the public-health Declaration

The Doha Development Round of trade talks was launched in 2001. Its most famous IP output is the Doha Declaration on the TRIPS Agreement and Public Health (14 November 2001), which:

affirmed that TRIPS should be interpreted to protect public health and promote access to medicines for all;
confirmed each member’s right to grant compulsory licences and to decide the grounds for them;
confirmed the freedom to allow parallel imports; and
extended the transition period for least-developed countries on pharmaceutical patents.

A later amendment (the Art. 31bis system, agreed 2005 and in force 2017) lets countries that cannot manufacture medicines themselves import cheaper generics made abroad under a compulsory licence.

🔑 KEY POINT — the Doha Declaration protects public health

The single sentence to remember: the Doha Declaration (2001) confirmed that TRIPS “does not and should not prevent members from taking measures to protect public health”. It legitimised compulsory licensing and parallel imports — the flexibilities India used in Bayer v Union of India (2014) to make a patented cancer drug affordable.

In Simple Terms: The WTO (from 1995) is the body that enforces TRIPS. Its dispute-settlement system — consultations, panel, Appellate Body, and ultimately trade sanctions — is the tooth the old IP treaties lacked. The Doha Declaration (2001) then tilted TRIPS toward public health, confirming that members may issue compulsory licences and allow parallel imports to keep medicines affordable.

🧩 WORKED EXAMPLE — a compulsory licence during a health crisis

Facts. A developing country faces a public-health emergency; a life-saving patented drug is priced out of reach. The government issues a compulsory licence letting a local firm make a cheap generic. The patent-holder’s country calls this a TRIPS breach.

Rule. TRIPS permits compulsory licences (Art. 31), and the Doha Declaration (2001) confirms members may use them to protect public health and decide the grounds themselves.

Apply. The compulsory licence is a recognised TRIPS flexibility, expressly endorsed at Doha; it is not a breach.

Conclusion. The country acts lawfully; any WTO complaint would fail, because Doha placed public health squarely within TRIPS — as India’s Bayer (2014) licence showed in practice.

flowchart TD
    ROOT["WTO (Marrakesh 1994, in force 1995) — enforces TRIPS"]:::root
    ROOT --> D["Dispute Settlement (DSU/DSB)"]:::leaf
    D --> D1["Consultations"]:::leaf
    D1 --> D2["Panel report"]:::leaf
    D2 --> D3["Appellate Body"]:::leaf
    D3 --> D4["Implement or face trade retaliation"]:::leaf
    ROOT --> H["Doha Declaration 2001 — TRIPS + public health"]:::impact
    H --> H1["Compulsory licences + parallel imports allowed"]:::impact
    classDef root fill:#FFF8DC,stroke:#000,stroke-width:1px,color:#000;
    classDef leaf fill:#E6F3FF,stroke:#1E3A8A,color:#000;
    classDef impact fill:#E8F5E9,stroke:#1B5E20,color:#000;
    linkStyle default stroke:#888,stroke-width:1px;

Case Laws

[C-6] Novartis AG v Union of India (2013) — India’s s.3(d) safeguard is TRIPS-compatible; the Doha public-health spirit in action.
Bayer Corporation v Union of India (2014) — India’s first compulsory licence (Nexavar) upheld under the Doha-endorsed flexibility.

📄 Full notes + Question Bank (₹199) — every topic in depth, model answers to all past KSLU questions, in one printable PDF. Get the bundle · 10 Solved Problems · All Intellectual Property Rights II topics